BIHC 

BIHC is a TNF blocker with anti-inflammatory activity. BIHC can significantly inhibit the proliferation of hepatocellular carcinoma (HCC) cells and exhibits potent cytotoxicity against the HepG2 cell line, capable of inducing cell apoptosis , while demonstrating relatively low toxicity towards normal hepatocytes. Additionally, BIHC can be used for research on inflammatory bowel disease (IBD)^[1].

BIHC (5-25 μM; 24-72 h) significantly inhibits the proliferation of hepatocellular carcinoma (HCC) cells with an in vitro anti-HepG2 cell activity IC₅₀ value of 6.4 μM, and inhibits the binding of TNF-α to its antibody in vitro with an IC₅₀ of 16.5 μM^[1].
BIHC (25 μM; 24 -72 h) induces apoptosis of liver cancer cells by disrupting the TNF trimer structure, inhibiting the NF-κB signaling pathway and its downstream gene products (such as cyclin D1, Mcl-1, survivin, Bcl-2) in HepG2 cells^[1].
BIHC (25 μM; 8 h) also significantly inhibits the invasion of HepG2 cells induced by CXCL12 (20 μM; 2 h)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BIHC (5 mg/kg; i.p.,Once daily for 5 days) can significantly alleviate dextran sulfate sodium (DSS)-induced colitis in Swiss albino mice, reduce the levels of pro-inflammatory factors TNF-α, IFN-γ, IL-1β, and IL-6, and upregulate the anti-inflammatory factor IL-10^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

492.91

C₂₆H₂₁ClN₂O₆

1642826-40-1

Solid

Off-white to light yellow

O=C1OC2=C(C(O)=C1C(C3=C(O)C4=C(C=CC=C4)OC3=O)C5=C(Cl)N=C(CCCC)N5)C=CC=C2

Room temperature in continental US; may vary elsewhere.

• [1]. Keerthy H K, Mohan C D, Siveen K S, et al. Novel synthetic biscoumarins target tumor necrosis factor-α in hepatocellular carcinoma in vitro and in vivo[J]. Journal of Biological Chemistry, 2014, 289(46): 31879-31890.  [Content Brief]